Effects of chronic Δ9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze

被引:63
作者
Nava, F
Carta, G
Colombo, G
Gessa, GL
机构
[1] Univ Cagliari, Dept Neurosci Bernard B Brodie, I-09042 Cagliari, Italy
[2] Neurosci SCARL, Cagliari, Italy
关键词
cannabinoids; microdialysis; T-maze;
D O I
10.1016/S0028-3908(01)00075-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Delta (9)-Tetrahydrocannabinol (Delta (9)-THC), the psychoactive ingredient of cannabis sativa, reduces both extracellular hippocampal acetylcholine concentration and correct alternation tasks in the T-maze. The principal aim of this study was to determine whether a chronic Delta (9)-THC treatment would induce tolerance both to the reduction of extracellular hippocampal acetylcholine concentration and memory deficit produced by the drug. Our results show that a chronic Delta (9)-THC treatment (5 mg/kg, i.p., twice daily for two weeks) did not produce tolerance to the inhibitory effects induced by the drug. Moreover, no strict temporal correlation between the two Delta (9)-THC effects was observed: the inhibition in extracellular acetylcholine concentration appeared only 80 min after treatment, while the reduction of correct alternation tasks in the T-maze began after 20 min. The cognitive and cholinergic effects induced by a chronic Delta (9)-THC treatment were completely blocked by the CB1 cannabinoid receptor antagonist SR 141716A, indicating an involvement of CB1 cannabinoid receptors in the persistent negative effects induced by the drug. These findings confirm the proposition that CB1 cannabinoid receptors mediate the negative effects induced by Delta (9)-THC both on hippocampal extracellular acetylcholine concentration and correct alternation tasks in the T-maze, and they indicate that these effects may be differentiated. However, the major outcome of this work is the demonstration that no tolerance to the two inhibitory effects develops after a chronic Delta (9)-THC treatment. (C) 2001 Published by Elsevier Science Ltd.
引用
收藏
页码:392 / 399
页数:8
相关论文
共 56 条
[21]   MARIJUANAS INTERACTION WITH BRAIN REWARD SYSTEMS - UPDATE 1991 [J].
GARDNER, EL ;
LOWINSON, JH .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (03) :571-580
[22]   Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors [J].
Gessa, G ;
Melis, M ;
Muntoni, A ;
Diana, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (01) :39-44
[23]   Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR 141716A [J].
Gessa, GL ;
Mascia, MS ;
Casu, MA ;
Carta, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 327 (01) :R1-R2
[24]   Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A [J].
Gessa, GL ;
Casu, MA ;
Carta, G ;
Mascia, MS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 355 (2-3) :119-124
[25]   Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes [J].
Gifford, AN ;
Bruneus, M ;
Gatley, SJ ;
Volkow, ND .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (03) :645-650
[26]  
Gifford AN, 1996, J PHARMACOL EXP THER, V277, P1431
[27]   Adverse effects of cannabis [J].
Hall, W ;
Solowij, N .
LANCET, 1998, 352 (9140) :1611-1616
[28]   Comparative effects of alcohol and marijuana on mood, memory, and performance [J].
Heishman, SJ ;
Arasteh, K ;
Stitzer, ML .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (01) :93-101
[29]  
HERKENHAM M, 1995, CANNABINOID RECEPTOR, P145
[30]  
HEYSER CJ, 1993, J PHARMACOL EXP THER, V264, P294